Aravive, Inc. (ARAV)
| Market Cap | 9.10M |
| Revenue (ttm) | 7.00M |
| Net Income (ttm) | -39.85M |
| Shares Out | 73.56M |
| EPS (ttm) | -0.88 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 578,296 |
| Open | 0.124 |
| Previous Close | 0.126 |
| Day's Range | 0.124 - 0.128 |
| 52-Week Range | 0.110 - 2.460 |
| Beta | 2.30 |
| Analysts | Hold |
| Price Target | 5.13 (+4,047.13%) |
| Earnings Date | Jan 9, 2024 |
About ARAV
Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops ... [Read more]
Financial Performance
In 2022, Aravive's revenue was $9.14 million, an increase of 22.78% compared to the previous year's $7.44 million. Losses were -$76.32 million, 94.9% more than in 2021.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for ARAV stock is "Hold." The 12-month stock price forecast is $5.13, which is an increase of 4,047.13% from the latest price.
News
Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer
HOUSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today annou...
Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023
HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today annou...
Aravive to Participate in William Blair's Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023
HOUSTON, July 14, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announ...
Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)
HOUSTON, June 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today annou...
Aravive To Participate in the Jefferies Global Healthcare Conference
HOUSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announ...
Aravive to Present Promising Updated Data from Phase 2 Trial of Batiraxcept in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma at ASCO 2023
HOUSTON, May 25, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announ...
Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma
HOUSTON, May 16, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announ...
Aravive to Host Virtual KOL Event on its Late-Stage Oncology Asset Batiraxcept
HOUSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announ...
Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting
HOUSTON, April 26, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today anno...
Aravive Appoints Carolina Petrini as Chief Commercial Officer
HOUSTON, April 11, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today anno...
Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
Company on Track for PROC Phase 3, Pivotal Trial Readout in Mid 2023; Ends Year with Strengthened Cash Position Company on Track for PROC Phase 3, Pivotal Trial Readout in Mid 2023; Ends Year with Str...
Aravive to Present Positive Updated Data from Phase 1b Trial of Batiraxcept in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma at the 2023 ASCO Genitourinary (GU) Cancers Symposium
HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today annou...
Aravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer
HOUSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today annou...
Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC
FDA decision based on new Phase 1b data: Objective Response Rate (ORR) of 57% and median Progression-Free Survival (PFS) of 11.4 months in patients with advanced or metastatic clear cell renal cell ca...
Aravive To Participate in Piper's 34th Annual Healthcare Conference
HOUSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail ...
Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement
HOUSTON, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today annou...
Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates
HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today repor...
Aravive Announces Approximately $41.5 Million Private Placement Financing
Priced At-The-Market with Substantial Participation from both New Life Sciences Specialist Investors as well as Large Existing Investors Priced At-The-Market with Substantial Participation from both N...
Aravive Receives Third Development Milestone from 3D Medicines
Milestone is Based on 3D Medicines' Initiation of the Phase 3 Clinical Trial for Platinum Resistant Ovarian Cancer in China Milestone is Based on 3D Medicines' Initiation of the Phase 3 Clinical Trial...
Aravive to Participate in the Cantor Fitzgerald Oncology & HemOnc Conference
HOUSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail...
Aravive to Participate in H.C. Wainwright 24th Annual Global Investment Conference
HOUSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail...
Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today repo...
Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer
Dr. Geller is a Board-Certified Medical Oncologist with over 30 years of experience in the biopharmaceutical industry and academia Dr. Geller is a Board-Certified Medical Oncologist with over 30 years...
Aravive Appoints Rudy Howard as Chief Financial Officer
HOUSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today annou...
Aravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced or Metastatic clear cell Renal Cell Carcinoma (ccRCC)
HOUSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announ...